Introduction
Since conventional treatments for malignant glioma have made little progress during the last several decades, the development of new therapeutic approaches has been the focus of intensive research. One such approach, herpes simplex virus thymidine kinase (HSV-tk)/gancyclovir (GCV) enzyme-prodrug therapy has shown the most promise and has several advantages. 1, 2 First, neurons are not damaged by this treatment because, when using retrovirus vectors, the HSV-tk gene is only transferred into dividing cells; thus, such treatment only targets proliferating cells. Second, tumor cells without HSV-tk gene transduction can be killed through the bystander effect by a mechanism that is not fully understood. 3 Results of clinical trials of HSV-tk/GCV therapy, however, have been disappointing. 4, 5 Thus, we attempted to develop a strategy that would improve the performance of HSV-tk/GCV therapy when applied in combination.
Our approach derived its rationale from recent progress that was made in understanding the mechanisms through which members of the Bcl-2 superfamily regulate apoptosis. The expression or function of each member of this superfamily is known to be regulated in response to specific death triggers. For example, in hematopoietic cells, an antiapoptotic member, Bcl-x L , is downregulated by cytokine withdrawal through inactivation of JAK-STAT pathways, [6] [7] [8] [9] [10] while DNA damage induced by ionizing radiation (IR) usually does not alter its expression levels. 11 In contrast, IR induces a proapoptotic member, Bax, by activating p53-dependent pathways, 12 while cytokine withdrawal does not. 7 The regulation of Bcl-x L and Bax through distinct pathways in hematopoietic cells might be conserved in glioma cells. Indeed, insulin-like growth factor I regulates the expression of Bcl-x L but not Bax, 13 which is induced in cells undergoing apoptosis as a result of DNA damage induced by IR or HSV-tk/GCV treatment. 14, 15 Because members of the Bcl-2 superfamily on the outer membrane of mitochondria integrate signals affecting cell fate and ultimately control the translocation of cytochrome c and other apoptosis-initiating proteins from the mitochondria to the cytosol, 16 enforced expression of different Bcl-2 superfamily members other than those induced by HSV-tk/GCV therapy might efficiently enhance its cytotoxic effects.
We and others recently established that the expression and/or function of Bim, a BH3-only member of death activators in the Bcl-2 superfamily, is upregulated by cytokine withdrawal through the inactivation of Rasphosphatidylinositol 3-kinase (PI3-K) pathways but not by DNA damage induced by IR in hematopoietic cells. 11, 17 It was also reported that Bim was induced in sympathetic neurons undergoing apoptosis that was triggered by the removal of neurotrophic factors. 18, 19 Thus, we speculated that Bim might be a candidate for enhancing the cytotoxic effect of HSV-tk/GCV on malignant glioma cells through different proapoptotic pathways. Bim was isolated independently by two groups that exploited its ability to bind Bcl-2 and Mcl1. 20, 21 Alternative splicing of Bim gives rise to three variants, BimEL, BimL, and BimS, each of which contains the BH3 domain and functions as a death inducer. In certain cell types, BimEL and BimL, but not BimS, bind to M r ¼8000 dynein light chain, LC8 (also PIN or Dlc-1), 22, 23 which negatively regulates the proapoptotic function of the former two isoforms. 24 In this study, we introduced the Bim genes into glioma cells in vitro and in vivo using adenovirus vectors. BimS but not BimL efficiently induced apoptosis in glioma cells. Moreover, BimS markedly enhanced the cytotoxic effects of HSV-tk/GCV therapy.
Results
Expression of the Bcl-2 superfamily members in human malignant glioma cell lines Our basic strategy to improve the performance of HSVtk/GCV therapy was to induce apoptosis in glioma cells through different cell death pathways. To test whether Bim was a good candidate, we analyzed protein expression in cell lines established from human malignant gliomas, as well as an HL60 human leukemia cell line as a positive control (Figure 1a , lane 1). Immunoblot analyses using antibodies specific for the Bcl-2 superfamily members revealed expression of Bcl-x L and Bim in glioma cells, while Bcl-2 protein was barely detectable (lanes 2-6). To identify genes that specifically responded to HSV-tk/GCV therapy, U251 cells were infected with AVC2-tk and were treated with 10 mM GCV after 48 h. Expression of Bax was induced as previously reported by others, 15 while expression levels of Bim were not altered ( Figure 1b) . These data suggested that the enforced expression of Bim may efficiently enhance the cytotoxic effects of HSV-tk/GCV therapy.
In vitro transfer of Bim genes to U251 malignant glioma cells using adenovirus vectors
In this study, we employed adenovirus vectors, which showed uniformly high infection efficiency in malignant glioma cells (data not shown). When using wild-type 293 cells for virus amplification at an MOI of 0.001, we obtained low-titer virus stocks around 1 Â 10 9 pfu/ml for AVC2-BimS and AVC2-BimL, which was less than one thousandth of that for AVC2-tk, because 293 cells were killed within 24 h of infection (data not shown). By using 293B cells, which stably overexpressed Bcl-x L protein (see Materials and methods), the titer of AVC2-BimS and Indeed, approximately 80% of these cells were positive for apoptosis using the TUNEL assay ( Figure 3b ) and had typical apoptotic changes including shrunken nuclei with perinuclear chromatin condensation, loss of pseudopods, and preservation of cytoplasmic organelles as shown by electron microscopy (Figure 4 ), indicating that BimS efficiently induced apoptosis in U251 cells. In contrast, cells infected by AVC2-BimL looked healthy (Figure 2a , right panel), and were negative for apoptosis using the TUNEL assay (Figure 3d ), despite their highlevel expression of BimL protein (Figure 2b ). Control cells that were infected by AVC2-tk without GCV treatment were also negative for TUNEL analysis ( Figure  3f ). These results suggested that the proapoptotic function of BimL was downregulated through the binding of LC8 and also that apoptosis induced by the AVC2-BimS was preferentially caused by BimS protein, rather than being due to nonspecific toxicity of the adenovirus. Rapid cell death induced by BimS but not by BimL was observed in other glioma cell lines including A172, T-430 and U373 (data not shown). 
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Enhancement of cytotoxic effects of HSV-tk/GCV treatment by BimS in vitro
We evaluated the cytotoxic effects of Bim proteins and their capacity to enhance HSV-tk/GCV treatment using the XTT assay. U251 cells were infected with AVC2-BimS, AVC2-BimL, or AVC2-tk at relatively high MOIs and XTT assay was performed after 3 days ( Figure 5a ). AVC2-BimS showed MOI-dependent cytotoxicity potential, while AVC2-BimL and AVC2-tk without GCV treatment (tk/PBS) had no cytotoxic effect at MOIs below 100. AVC2-tk followed by GCV treatment (tk/GCV) showed no effect at this time point, implicating BimS in the mediation of this rapid cytotoxic effect. Next, we infected U251 cells with AVC2-BimS or AVC2-BimL as the sole adenovirus vector or in combination with AVC2-tk at relatively low MOIs and tested cytotoxicity on day 7 ( Figure 5b ). Neither AVC2-BimL, tk/PBS, nor the combination of these treatments showed cytotoxicity. However, AVC2-BimS, tk/GCV, and combinations containing either of these two treatments (ie, combination of AVC2-BimS and tk/PBS, and combination of AVC2-BimL and tk/GCV) had cytotoxic effects at an MOI of 25. Intriguingly, cytotoxic potential obtained by the combination of tk/GCV and BimS (tk/ GCV+BimS) treatment seemed to be higher than that obtained by an additive effect of tk/GCV and BimS. For testing statistical significance of joint effect of tk/GCV and BimS, a likelihood ratio test was conducted in the following ways. Let y ij (j¼1,y,8; i¼1,2,3) be the response variable at the jth MOI level for the ith treatment, where i¼1,2, and 3 means the treatment with BimS, tk/GCV, and tk/GCV+BimS, respectively. Then we consider the Weibull curve model
where e ij is the error term, and m i , and a i are unknown positive parameters. By transforming y ij to
we induced the following simple linear model,
where z is the constant for adjustment such that total variance of z ij is unity, and x is the constant for each response being common at d j ¼0. The null hypothesis was formulated as H 0 :b 3k ¼b 1k +b 2k (k¼0,1), where there exists no joint effect of 'tk/GCV+BimS'. Let L be the likelihood with no restriction and L 0 be one under H 0 . Then the likelihood ratio test statistic T¼À2log(L 0 /L) is asymptotically distributed as Chi-squared distribution having the numbers of restricted parameters as its degree of freedom. The result shows that H 0 is rejected with a high significance level of Po0.01, which means that the joint effect of tk/GCV and BimS can be expected more than the independent multiplier one ( Figure 5c ). Similar results were observed in U373 and T-430 cells (Figures 5d  and e) . 
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Enhancement of the anti-tumor effect of tk/GCV treatment by BimS in an animal model
The encouraging results described above prompted us to perform experiments in an animal model to test the potential of BimS for enhancing the performance of HSV-tk/GCV therapy. U251 cells (4 Â 10 6 ) were inoculated subcutaneously into nude mice together with AVC2-BimS, AVC2-BimL, AVC2-tk, or AVC2-LacZ adenovirus vectors, which were injected either as a sole vector or in combination. When a single injection of AVC2-BimL, AVC2-LacZ, or AVC2-tk (followed by i.p. injections of PBS) was administered to the tumor, continuous tumor growth was observed (Figure 6a) . Injection of adenovirus vectors containing either AVC2-BimS or AVC2-tk (followed by i.p. injections of GCV) checked tumor growth temporarily, but eventually the tumor began to regrow. As expected, the combination treatment with AVC2-BimS and AVC2-tk (followed by i.p. injections of GCV) inhibited tumor regrowth.
To test the joint effect of tk/GCV and BimS treatment in animal model, we applied the growth curve model (eg Potthoff and Roy
25
) for the tumor growth data. The response is 'logarithmic transformed tumor size', the time variable is 'Days after treatment', and nine treatments are used as the class variables. For every treatment group, a quadratic growth curve is fitted through the least-squares method (Figure 6b) . Then a set of the null hypotheses about effects of 'tk/GCV+BimS', 'tk/GCV', and 'BimS', which we are interested in, were listed in the table. The estimated coefficients for the above three treatments were statistically compared by Wald-type T 2 statistic that is subject to Chi-squared distribution asymptotically under the null hypothesis. 26 The results showed that all of the null hypotheses were rejected with high significance levels (Po0.01), indicating that the strong joint effect of 'tk/GCV+BimS' compared with the expected additive effect of 'tk/GCV' and 'BimS'.
To confirm that BimS induced apoptosis in tumor cells in this animal model, expression of BimS and 
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observed that tumor cells expressing Bim proteins at high levels had TUNEL-positive shrunken nuclei ( Figure  7b , arrowheads). In contrast, cells expressing Bim at background levels had TUNEL-negative healthy nuclei (arrows), suggesting that BimS induced apoptosis in U251 cells also in the animal model. Induction of apoptosis by BimS was again confirmed by electron microscopy. Three days after infection by AVC2-BimS, cells carrying fragmented nuclei with condensed chromatin were readily found ( Figure 4d ) and apoptotic bodies phagocytosed by surrounding cells were observed (Figure 4e ).
Discussion
In this paper, we transferred the BH3-only death activator genes, BimL and BimS, to malignant glioma cells using adenovirus vectors in an attempt to enhance HSV-tk/GCV-mediated killing in vitro and in vivo. Using 293B cells that overexpressed Bcl-x L , we were able to protect virus-producing cells from apoptosis induced by Bim and obtained high titers of adenovirus stocks that were capable of transferring genes into tumors in nude mice. BimS, but not BimL, induced rapid apoptosis in malignant glioma cells, in spite of the fact that BimL seemed to be expressed at higher levels than BimS as determined by immunoblot analysis (Figure 2b ). In the case of the 293 cells, however, both variants of Bim equally induced cell death. Bim is controlled by several mechanisms. First, its expression levels are regulated by cytokines and neurotrophic factors through Ras and PI3-K pathways in hematopoietic cells 11, 17 and in neurons. 19 Bim is also phosphorylated by cytokine-initiating signal pathways, although it is not known whether the phosphorylation of Bim regulates its function. 11 In addition, the subcellular localization of Bim protein was reported to be regulated by cytokines. 24 BimEL and BimL, but not BimS protein, form a complex with an M r ¼8000 dynein light chain, LC8 (also PIN or Dlc-1), 22, 23 which is a component of the dynein motor complex. In healthy cells, the Bim/LC8 complex binds to the intermediate chain of the dynein motor complex on the microtubules, which is physically separated from anti-apoptotic Bcl-2 family members on the surface of mitochondria. Apoptotic triggers dissociate the Bim/LC8 complex from the dynein intermediate chain by still undetermined mechanisms, enabling Bim to bind to antiapoptotic Bcl-2 family members and inhibit their function. The contribution of these three mechanisms to the regulation of Bim function is likely to be different in different cells. For instance, among murine interleukin (IL)-3-dependent cell lines, IL-3 starvation does not affect the expression levels of Bim proteins in FDC-P1 cells, while its subcellular distribution is regulated by IL-3 through the LC8-dependent mechanism. 24 In contrast, Bim proteins are induced by IL-3 withdrawal in Baf-3 and FL5.12 cells. 11, 17 Moreover, forced (but not over) expression of BimEL or BimL readily induced apoptosis in Baf-3 cells even in the presence of IL-3, 17 suggesting that the expression levels of Bim proteins are critical for determining the fate of Baf-3 cells. These findings may help to explain the apparent differences in responsiveness to BimL in 293 and U251 cells.
BimS markedly enhanced the cytotoxic effect of tk/GCV therapy. In our animal model, although BimS and tk/GCV therapy reduced tumor volume rapidly, surviving cells eventually regrew (Figures 6a  and b) . Indeed, 3 days after infection, we observed tumor cells that expressed Bim protein at low levels and had healthy-looking nuclei (Figure 7b ). These cells may be more efficiently eliminated by the combination of BimS and tk/GCV therapy than BimS alone. This synergistic effect is unlikely due to Bim's ability to induce cell death in a cell cycle phase independent fashion, 27 because we also observed this effect in in vitro experiments ( Figure  5 ), where almost all cells were proliferating. Although we do not know the precise mechanism of this effect, it is possible that the simultaneous expression of BimS, which is the downstream target of growth factors/Ras-PI3-K pathways, and Bax (or other proapoptotic Bcl-2 family members) induced by HSV-tk/GCV treatment, served to enhance their respective cytotoxic potentials in the process by which they integrate their fate-determining signals. Alternatively, rapid induction of apoptosis in glioma cells by BimS may somehow have enhanced the cytotoxicity of HSV-tk/GCV therapy in the later phase. Recent studies suggested the possibility that gene products in cells undergoing apoptosis can be transferred from one tumor cell to another in the process of apoptosis, 28 since apoptotic bodies can be phagocytosed not only by macrophages but also by tumor cells. 29, 30 Thus, HSV-tk protein expressed in cells infected by both AVC2-BimS and AVC2-tk might be transferred to neighboring tumor cells through phagocytosis and render these cells sensitive to GCV. We are currently investigating the molecular mechanism through which BimS enhances the cytotoxicity of HSV-tk/GCV therapy.
Cell cycle-independent induction of apoptosis by BimS may be useful in improving the efficacy of HSV-tk/GCV as a treatment of human disease by killing resting tumor cells, since the mitotic index in human malignant gliomas is much lower than that in animal models. 31 However, such treatment is likely to damage normal brain tissue including neurons. To avoid this problem, we attempted to express Bim protein using promoters of genes specifically expressed in malignant glioma cells but not in neurons, such as glial fibrillary acidic protein (GFAP) 32, 33 or myelin basic protein (MBP), 34 ,35 but we were unable to obtain sufficient expression of Bim to induce cell death (data not shown). Development of a powerful glioma-specific promoter along with a tumor targeting vector system would be another key step to the application of this therapeutic approach in humans. 
Construction and preparation of adenoviral vectors
The recombinant adenoviral vectors were constructed using an adenoviral DNA-protein complex lacking an insert (AVC2.null), 36 which contained the cytomegalovirus (CMV) promoter, a simian virus (SV)-40 intron, and the SV-40 polyadenylation signal. To generate AVC2-BimS or AVC2-BimL vectors encoding either BimS or BimL protein as well as the enhanced green fluorescence protein (EGFP) as a marker, a SpeI-ClaI fragment containing either BimS or BimL cDNA and an internal ribosomal entry site (IRES) sequence followed by the EGFP cDNA in frame was inserted into the XbaI and NspV sites in AVC2.null using the direct in vitro ligation technique. 36 To obtain AVC2-tk, the HSV-tk gene was excised from pAVS6TK 37 by digestion with XbaI and ClaI and ligated into AVC2.null. The adenovirus vector AVC2-LacZ harboring a b-galactosidase expression cassette has been previously described. 38 The ligated DNAprotein complex was introduced into 293 cells using the calcium phosphate transfection method. Viral isolates were screened and amplified using standard techniques. 36 Recombinant adenovirus was titered by determination of the median tissue culture infection dose (TCID 50 ). Viral stocks were stored in 10% glycerol and kept at À801C until use.
Antibodies, immunoblot analysis
Anti-human Bcl-2 monoclonal antibody and anti-human Bcl-x polyclonal antibody were purchased from BD Transduction Laboratories (Lexington, KY, USA). Bax antibody was purchased from BD PharMingen (San Diego, CA, USA). Anti-Bim polyclonal antibody was raised by us and described elsewhere.
11 Affinity purification of the Bim antibody was performed using cyanogen bromide-activated Sepharose 4B (Amersham, Piscataway, NJ, USA) conjugated with antigen protein according to standard procedure. Immunoblot analysis was performed as described previously. 6, 11 In each experiment, total cell extracts from 1 Â 10 5 glioma cells or from 1 Â 10 6 HL-60 cells were analyzed.
Terminal deoxynucleotidyltransferase-mediated nick end labeling (TUNEL) analysis U251 cells were infected with AVC2-BimS or AVC2-BimL at an MOI of 20. Thirty-six hours later, cells were harvested and fixed with 4% paraformaldehyde for 20 min, and the TUNEL assay was performed using the Apoptosis Detection Kit according to the manufacturer's directions (Promega, Madison, WI, USA). Cells were then stained with 1 mg/ml propidium iodide (PI) and 0.1% Evans blue for 10 min at room temperature. After centrifugation with cytospin, incorporation of dUTP was visualized by fluorescence microscopy.
Microculture tetrazolium dye (XTT) assay
Cytotoxicity assays were performed using a vital stain XTT assay using the Cell Proliferation Kit II (Roche, Basel, Switzerland). U251 cells were seeded on 96-well plates and infected with AVC2-tk, AVC2-BimS, AVC2-BimL, or AVC2-tk in combination with AVC2-BimS or AVC2-BimL at a variety of MOIs. Forty-eight hours after AVC2-tk infection, either GCV at a final concentration of 10 mM or phosphate buffer saline (PBS) was added in the culture medium. Three or 7 days after infection, the tetrazolium salt 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxyaniline (XTT), which is metabolized to formazan by intact mitochondrial dehydrogenases, and an electron coupling reagent were added and cells were incubated for a further 24 hours. The viability of the cells was estimated on the basis of formazan formed, which was detected spectrophotometrically.
